Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerThe Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsIncorporation of tissue-based genomic biomarkers into localized prostate cancer clinicsPSA and beyond: alternative prostate cancer biomarkersActive surveillance and focal therapy for low-intermediate risk prostate cancerPotential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerBiomarkers in prostate cancer: what's new?Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohortPrognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.Active surveillance for prostate cancer: current evidence and contemporary state of practiceProstate cancer biomarkers: Are we hitting the mark?How Precisely Can Prostate Cancer Be Managed?Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymesHigh-throughput analysis and characterization of Astragalus membranaceus transcriptome using 454 GS FLXPrognostic outlier genes for enhanced prostate cancer treatment.Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancerExternal validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancerCopy number alteration burden predicts prostate cancer relapseActive surveillance in men with low-risk prostate cancer: current and future challenges.Gleason 6 Prostate Cancer: Translating Biology into Population Health.Prognostic value of discs large homolog 7 transcript levels in prostate cancer.Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.Risk stratification of prostate cancer in the modern era.Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohortAdverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.RNA biomarkers to facilitate the identification of aggressive prostate cancerCost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.New advances in focal therapy for early stage prostate cancer.Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung CancerApplying precision medicine to the active surveillance of prostate cancer.Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Clinically available RNA profiling tests of prostate tumors: utility and comparisonBiomarkers in prostate cancer surveillance and screening: past, present, and future.Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinomaBiomarkers for prostate cancer: present challenges and future opportunities.Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies.Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy.Novel concepts for risk stratification in prostate cancer.
P2860
Q26738703-48DF0E50-EDA9-4DE2-B5AD-0F04A20B6754Q26750672-B1CC0BB6-C6E7-4774-9D1B-AAEA04DE16D4Q26752510-82C51CA2-4D48-4AD6-B576-966A51F90F92Q26770646-D60E43BE-E938-4D5C-B03F-8565666F4350Q26773641-5420C081-4F00-4F63-8D48-0E6063987DFEQ26784517-0135C7BE-42D7-4272-BB1B-2DB938B69256Q27026210-720DFD8E-96C8-4455-8D86-0D64F2993DC4Q27331050-58706C88-595F-4D00-A3D4-1AA0C00263ADQ27852034-8878F7F2-EAF9-4B49-BFE5-E6EE93C42A2DQ28066534-DA3A0C7B-E64C-40E7-88C1-560DE045AD39Q28071654-07F82A85-739E-4A9B-BAAB-04B8FB189B42Q28078942-1F1027D9-C228-4407-84A1-3FBFEAC22006Q28085759-C6EC05A5-76BD-40AD-8DE1-5751B58ABE2EQ28538783-4FAA9997-0AE6-4AAF-8BEE-D6387765019DQ30244674-3EF1A1A6-9AD9-4613-B24A-FE6BBC02D790Q30938412-E0276108-80EE-479C-BFBF-53E1196EBDCBQ33696684-CAB28269-7E63-4C89-BFBE-BA7D23D4E952Q34002312-FFCE4EF0-B73A-487D-BECD-AA8AB6ACDCC7Q34448113-38EF245F-EFE3-43CA-ACB3-72554059625FQ34470640-0DB1C45F-1C42-4C82-B8D3-4C723178F8DAQ35070576-6BEE2ED6-FA65-4AE5-A897-054149F46836Q35536948-CCD7B22E-BD6F-401E-A65D-D377F17573ACQ35678391-D7F86CDF-9933-411D-8079-D576EA8FAB00Q35680101-159B20E6-2321-4164-9250-DA4B6175F199Q35909631-F2A4E535-9318-4754-B134-B827AF4A59A6Q36201978-5460631B-FBD7-4980-B2C2-024654FB2794Q36260364-8FE51111-0AE6-4F92-A660-38B2B928DB7CQ36371617-691AC0C9-9113-4B8B-BCD3-DF21A0EE0D02Q36411076-8A51B0C8-8E4F-4D34-A4BA-BEC83B5A3721Q36558386-56C91C32-FE01-4391-9F9D-AED9AA8266F7Q36592871-1DA1DA86-8BA5-427F-B858-EB3BBF7A555DQ36959119-A5D0FADE-EEE7-4F05-9AA8-1C1F71556DD8Q37029385-ED4E43CC-0E73-4FBB-8ECA-1C0D3BAB1567Q37113181-77CBD721-A023-4E91-9058-4FE0AFDCE33BQ37300931-82CC511E-82CA-417E-BC90-EF804AAB6D39Q37325311-04B77A44-B616-4868-97B6-D08232084C47Q37474443-CA6C58B0-3281-4D82-9C59-066889E14FC0Q37619763-6B60BCD3-538D-4C43-BD16-486490D69A21Q37665314-CCA6E004-05D3-4B88-8F2D-14CC90325755Q37708177-205EF183-6954-49AF-AB7E-964288E0AB9A
P2860
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prognostic value of a cell cyc ...... managed needle biopsy cohort.
@ast
Prognostic value of a cell cyc ...... managed needle biopsy cohort.
@en
type
label
Prognostic value of a cell cyc ...... managed needle biopsy cohort.
@ast
Prognostic value of a cell cyc ...... managed needle biopsy cohort.
@en
prefLabel
Prognostic value of a cell cyc ...... managed needle biopsy cohort.
@ast
Prognostic value of a cell cyc ...... managed needle biopsy cohort.
@en
P2093
P2860
P356
P1476
Prognostic value of a cell cyc ...... managed needle biopsy cohort.
@en
P2093
C S Foster
D M Berney
J S Lanchbury
P2860
P2888
P304
P356
10.1038/BJC.2012.39
P407
P50
P577
2012-02-23T00:00:00Z